cytokine storm, page-17

IMP761 Overview............from January Corporate report..
• The Concept: treating the cause of autoimmune
diseases, not just the symptoms
• The Target: the self-peptide specific memory T cells
harboring LAG-3
• The Tool: an agonistic LAG-3-specific mAb down-modulating self-peptide-induced TCR
signaling
• The Evidence (1)*: in vitro down-modulation of peptide-induced human T cell proliferation
and activation
• The Evidence (2)*: in vivo down-modulation of peptide-induced T cell infiltration /
inflammation at the tissue site in a NHP model
• IP: 1 family - composition of matter & methods of treatment, expiry 2036
• The Status: cell line development ongoing and GMP manufacturing preparations
underway in order to progress to clinical development

Note: the concept of imp761, this is where it differs from imp731...
If the C-19 research eventuates it seems it will be a treatment of symptoms rather than cause at this stage...
also note: GSK are testing an arthritis treatment for C-19 at this point...
We will just have to wait and see what comes of it all...
Also of interest is Mesoblast are hoping of $100M finance to expand their C-19 treatment..